Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
It is available for adults with a body mass index (BMI) of at least 35 kg/m, or between 30-34.9 kg/m with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity
Metabolic Syndrome Resolution Post-hoc analysis of SURPASS trials demonstrated substantial reductions in metabolic syndrome prevalence: Significant improvements in multiple cardiovascular risk factors simultaneously Reductions in blood pressure, improved lipid profiles, and decreased waist circumference Resolution of metabolic syndrome criteria in a substantial proportion of participants Potential long-term cardiovascular benefits from comprehensive metabolic improvements Cardiovascular and Metabolic Comorbidities Heart Failure with Preserved Ejection Fraction (HFpEF) The SUMMIT phase 3 trial evaluated GLP2 in adults with HFpEF and obesity: Statistically significant reduction in heart failure outcomes (composite endpoint) Improvements in heart failure symptoms and physical limitations measured by Kansas City Cardiomyopathy Questionnaire Enhanced exercise capacity as measured by 6-Minute Walk Test Distance Reduction in high-sensitivity C-reactive protein (inflammation marker) These findings established GLP2 as the first incretin therapy to demonstrate benefits on heart failure outcomes in this population
Without adequate L-Glutamine, the enterocytes literally starve, leading to the rapid degradation of the intestinal barrier
It's perfectly normal to have concerns about pain during or after an injection
34 These studies suggest that the impact of lifestyle interventions on breast cancer recurrence may be mediated by effective weight loss and adherence, and importantly, even modest weight change can be associated with meaningful clinical benefit
US$ 22.47
US$ 28.84
US$ 22.73
US$ 28.51
US$ 25.14
US$ 22.01
US$ 24.46
US$ 25.98
US$ 24.60
